Relmada Therapeutics
Dr. Paolo Manfredi is specialized in Neurology and Psychiatry, Pain Medicine, and in Hospice and Palliative Care. He has completed fellowships at MD Anderson Cancer Center and Massachusetts General Hospital, where he obtained the Golden Needle Award. He has served as the Director of the Pain Management and Palliative Care Program at Mount Sinai Medical Center where he was an Assistant Professor in Neurology, Anesthesia, and Geriatric Medicine.
For over ten years Dr. Manfredi has served as the Pain and Palliative Care Fellowship director at Memorial Sloan Kettering Cancer Center. Dr. Manfredi's research is focused on novel NMDAR channel blockers for the treatment of neuropsychiatric disorders. Dr. Manfredi is co-founder of Relmada and co-inventor of REL-1017, a novel NMDAR channel blocker.
This person is not in any teams
This person is not in any offices
Relmada Therapeutics
2 followers
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain.